- Home
- ENGN vs OSUR Comparison
ENGN vs OSUR Comparison
Compare ENGN & OSUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENGN
- OSUR
- Stock Information
- Founded
- ENGN 1999
- OSUR 2000
- Country
- ENGN Canada
- OSUR United States
- Employees
- ENGN N/A
- OSUR N/A
- Industry
- ENGN
- OSUR Medical/Dental Instruments
- Sector
- ENGN
- OSUR Health Care
- Exchange
- ENGN Nasdaq
- OSUR Nasdaq
- Market Cap
- ENGN 317.6M
- OSUR 289.4M
- IPO Year
- ENGN N/A
- OSUR 1986
- Fundamental
- Price
- ENGN $6.32
- OSUR $3.69
- Analyst Decision
- ENGN Strong Buy
- OSUR Hold
- Analyst Count
- ENGN 9
- OSUR 2
- Target Price
- ENGN $29.78
- OSUR $5.50
- AVG Volume (30 Days)
- ENGN 206.9K
- OSUR 1.0M
- Earning Date
- ENGN 12-19-2024
- OSUR 11-06-2024
- Dividend Yield
- ENGN N/A
- OSUR N/A
- EPS Growth
- ENGN N/A
- OSUR N/A
- EPS
- ENGN N/A
- OSUR 0.15
- Revenue
- ENGN N/A
- OSUR $224,263,000.00
- Revenue This Year
- ENGN N/A
- OSUR N/A
- Revenue Next Year
- ENGN N/A
- OSUR N/A
- P/E Ratio
- ENGN N/A
- OSUR $24.43
- Revenue Growth
- ENGN N/A
- OSUR N/A
- 52 Week Low
- ENGN $4.42
- OSUR $3.58
- 52 Week High
- ENGN $18.40
- OSUR $8.45
- Technical
- Relative Strength Index (RSI)
- ENGN 36.76
- OSUR 41.00
- Support Level
- ENGN $5.60
- OSUR $3.76
- Resistance Level
- ENGN $6.54
- OSUR $4.14
- Average True Range (ATR)
- ENGN 0.67
- OSUR 0.18
- MACD
- ENGN -0.14
- OSUR -0.02
- Stochastic Oscillator
- ENGN 22.43
- OSUR 18.33
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
About OSUR OraSure Technologies Inc.
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.